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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.11.015Objective: Use of antifibrinolytic agents reduces the risk of bleeding and decreases
the need for blood product use in patients undergoing cardiac surgery. The purpose
of this study was to determine whether perioperative use of tranexamic acid
decreases the rate of saphenous vein graft patency in the early postoperative period
after conventional coronary artery bypass grafting surgery.
Methods: A total of 312 patients scheduled for elective coronary artery bypass
grafting surgery with cardiopulmonary bypass were randomized to receive either
tranexamic acid 100 mg/kg (n  147) or placebo (n  165) in a double-blinded
fashion before the initiation of cardiopulmonary bypass. Saphenous vein graft
patency was assessed with magnetic resonance imaging 5 to 30 days after
surgery.
Results: Both groups were comparable with respect to baseline demographic data
and surgical characteristics. A total of 237 (76%) patients underwent magnetic
resonance imaging assessment. A total of 297 saphenous vein grafts were
performed and 253 (85.2%; 95% confidence interval, 83.5%-86.9%) were seen
in the tranexamic acid group, and 265 saphenous vein grafts were performed and
231 (87.2%; 95% confidence interval, 85.5%-88.9%) were seen in the placebo
group (P  .4969). The blood loss and blood product transfusion rates in the
tranexamic acid group were significantly lower than in the placebo group. There
was no difference between groups with respect to postoperative morbidity and
mortality.
Conclusions: The administration of tranexamic acid before cardiopulmonary bypass
did not seem to compromise early venous graft patency rates but reduced periop-
erative blood product transfusion rates. Consequently, tranexamic acid could be
advocated for routine use in patients undergoing conventional coronary artery
bypass grafting surgery.
Coronary revascularization surgery is increasingly performed on older pa-tients (65 years) with extensive coronary artery pathology who haveimpaired left ventricular function, decreased physiological reserve, and
multiple comorbid conditions.1-3 It is estimated that approximately half a million
patients undergo cardiac surgical procedures in the United States annually: this costs
approximately $9 billion per year. The increase in resource utilization and health-
care costs has resulted in changing health-care practices to maximize cost contain-
ment and in efficient resource utilization by widespread adoption of fast-track
cardiac surgery pathways.4
Postoperative hemostasis is an integral part of a fast-tracking process to reduce
the exposure of patients to blood transfusion–related complications and decrease
heavy demands on blood-bank resources.5-7 The use of antifibrinolytic agents before
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perioperative bleeding and has been shown to be a cost-
effective way to reduce the need for blood products.8-15
Nevertheless, perioperative inhibition of fibrinolysis may
increase the rate of early graft occlusion rates, thus preclud-
ing its routine use in patients undergoing coronary revascu-
larization procedures. Concerns have been expressed re-
garding the use of a natural serine proteinase inhibitor,
aprotinin, and saphenous vein graft (SVG) thrombosis after
cardiac surgery. A recent report from the International Mul-
ticenter Aprotinin Graft Patency Experience trial demon-
strated a significant increase in early SVG occlusion rates in
aprotinin-treated patients when compared with placebo.16
Furthermore, the current cost of aprotinin prevents its rou-
tine use in many institutions that identify more cost-effec-
tive alternatives, such as the synthetic lysine analogs tran-
examic acid (TA) and -aminocaproic acid. The current cost
of aprotinin and TA in our institution is $1348CAD and
$147CAD per case, respectively. Although TA is more
economical, there is currently no evidence to support our
contention that TA can be used safely without compromis-
ing coronary graft patency. The purpose of this study was to
determine whether the perioperative use of TA decreases
early SVG patency rates after coronary artery bypass graft-
ing (CABG) surgery.
Methods
Study Population
After institutional review board approval, informed consent was
obtained from 312 patients scheduled for elective CABG surgery
with CPB. Patients with a history of claustrophobia; known con-
traindications to magnetic resonance imaging (MRI); bleeding
disorders; preoperative hemoglobin less than 135 g/L; symptom-
atic peripheral vascular disease; connective tissue disease; age
older than 80 years; impaired renal function (creatinine 2.0
mg/dL); active liver disease; known allergies to TA, aspirin, or
contrast dye (Omnipaque; Sterling Winthrop, Inc, Collegeville,
Pa); or left ventricular function ejection fraction less than 20%
were excluded from the study.
Description of Management Strategies
A computer-generated randomization code in blocks of 4 was used
to assign patients to receive either TA or placebo in a double-
blinded fashion. The hospital pharmacy department prepared iden-
tical bags of 100-mL solution containing either TA 100 mg/kg or
5% dextrose (placebo), which was administered intravenously over
20 minutes after the induction of anesthesia.
All routine cardiac medications were continued up to the morn-
ing of the operation. All patients received premedication with
lorazepam 2 mg 1 to 2 hours before the operation. The anesthetic
technique was standardized to include fentanyl (10-20 g/kg),
midazolam (0.1 mg/kg), pancuronium (0.15-0.20 mg/kg), and
isoflurane (0.5%-1.5%). The initial dose of heparin was 300 U/kg.
Additional heparin was given as necessary to maintain activated
clotting time greater than 400 seconds. Monitoring included con-
tinuous direct arterial blood pressure, central venous pressure,
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with continuous ST-segment analysis, pulse oximetry, capnogra-
phy, and nasopharyngeal temperature measurements.
All patients were operated on by the same team of surgeons at
Toronto General Hospital. Patients underwent median sternotomy
with harvesting of the saphenous veins and internal thoracic arter-
ies (ITAs) as conduits. Myocardial protection was achieved with
intermittent antegrade and often retrograde cold-blood cardiople-
gia. Management of CPB included systemic temperature drift to
33°C, alpha-stat pH management, mean perfusion pressure be-
tween 50 and 90 mm Hg, pump flow rates of 2.0 to 2.4
L · min1 · m2, and hematocrit greater than 20%. Before sepa-
ration from CPB, patients were rewarmed to 37°C. After separa-
tion from CPB, heparin was neutralized with protamine 1 mg/100
U of heparin. After surgery, patients were transferred to the inten-
sive care unit for postoperative ventilation. Sedation was achieved
with propofol infusion (0.5-4 mg · kg1 · h1) and morphine
boluses. Patients were extubated according to the following crite-
ria: patient responsive and cooperative, arterial oxygen saturation
94% or more with fraction of inspired oxygen 60% or less,
complete reversal of neuromuscular blockade, PaCO2 35 to 55 mm
Hg, stable hemodynamics, absence of uncontrolled arrhythmia,
and nasopharyngeal temperature greater than 36°C.
If the postoperative mediastinal chest tube drainage was 300
mL/h or more despite the standard therapeutic measures, the staff
hematologist was consulted with respect to the administration of
open-labeled TA 100 mg/kg without breaking the randomization
code, regardless of the patient group assignment.
Coronary MRI
Cine MRI of SVG patency assessment was performed between 5
and 30 days after surgery. After localizing spin-echo coronal
images were obtained, multiple axial multisliced interleaved cine
MRI acquisition was performed; each consisted of two to four 5-
to 10-mm slices. Eight to 24 frames per cardiac cycle were
obtained from the superior main pulmonary artery to the inferior
left ventricle. Images were transferred to the film and read by an
independent observer without knowledge of the treatment group
but with knowledge of the original graft insertion. Graft patency
was defined by the presence of a bright graft flow signal not
corresponding to the normal vessels and identified on multiple
frames at multiple levels separating the great vessels and the
epicardial surface of the heart.
Statistical Analysis
Comparability of both groups was tested with the use of 2
statistics on qualitative variables and 1-way analysis of variance on
quantitative variables. The primary outcome of graft patency was
analyzed with a 2  2 contingency table, which included 2
possible outcomes: the grafts seen or not seen by the MRI. Con-
fidence intervals for proportions were calculated at 95%. A P value
less than .05 was considered significant. All analyses were per-
formed on an intention-to-treat basis. Statistical analysis was con-
ducted with SPSS computer software (SPSS Inc, Chicago, Ill).
Results
A total of 312 patients were randomized according to a
computer-generated randomization code: 147 patients in the
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PTA group and 165 patients in the placebo group. There were
no differences in the baseline demographic data or surgical
characteristics between groups (Table 1). None of the pa-
tients received aspirin or other antiplatelet agents within 7
days of the operation. Open-labeled TA was administered to
4 patients in the TA group and 24 patients in the placebo
group in the postoperative period. A total of 237 (76%)
patients underwent MRI assessment for graft patency. MRI
was not performed in 29 patients from the TA group and 45
patients from the placebo group (P  .11). The reasons for
TABLE 1. Demographic variables and operative character-
istics
Baseline characteristic
TA group
(n  147)
Placebo group
(n  165)
Age, y (mean  SD) 59.9 8.9 60.0 8.3
Weight, kg (mean  SD) 79.8 12.0 81.6 12.0
Male, n (%) 128 (87.0) 147 (89.0)
BSA, m2 (mean  SD) 1.92 0.18 1.95 0.18
EF  40%, n (%) 32 (22.0) 40 (24.0)
Coexisting illness, n (%)
Hypertension 77 (53.1) 90 (56.3)
Myocardial infarction 71 (48.3) 81 (49.4)
Diabetes 41 (27.9) 52 (31.5)
Peripheral vascular disease 43 (29.4) 42 (25.9)
Stroke 3 (2.0) 7 (4.3)
Preoperative medication, n (%)
-Blockers 82 (56.2) 78 (47.3)
Calcium channel blockers 66 (47.3) 66 (40.0)
Aspirin 118 (80.8) 130 (81.8)
NSAID 2 (1.4) 2 (1.2)
Preoperative laboratory
variables (mean  SD)
PTT (s) 31.0 23.2 32.1 16.0
PT (s) 10.9 1.1 11.1 1.4
Hemoglobin (g/dL) 141.2 11.7 143.7 11.6
Platelet count (103/mm3) 223 58 229 55
Creatinine (mg/dL) 93.1 16.8 92.4 19.7
Intraoperative variables (mean
 SD)
CPB time (min) 80.7 29.9 82.0 20.0
Minimum CPB temperature
(°C)
33.5 1.1 33.4 1.2
Saphenous vein grafts, n
(mean  SD)
2.7  0.7 2.8 0.7
LITA grafts (%) 97.2 100
Total heparin, U (mean  SD) 39,225 12,903 37,558 12,874
Total protamine, mg (mean 
SD)
406.9 106.5 405.0 118.3
TA, Tranexamic acid; BSA, body surface area; EF, ejection fraction; NSAID,
nonsteroidal anti-inflammatory drug; PTT, partial thromboplastin time; PT,
prothrombin time; CPB, cardiopulmonary bypass; LITA, left internal tho-
racic artery.MRI cancellation included death, stroke, presence of pacing
The Journal of Thoraciwires at a time of MRI-allocated time, claustrophobia, and
patient refusal.
There was no significant difference with respect to early
SVG patency between the 2 groups (Table 2; P  .4969).
The confidence intervals for a test group were estimated by
using the binomial distribution. Because of the large sample
size within each test population, the normal approximation
was used. The binomial confidence limits were approxi-
mately 1.7% for each of the classes. The 95% confidence
interval of the placebo group was 85.5% to 88.9%, and the
95% confidence interval of TA group was 83.5% to 86.9%.
The null hypothesis of the test would have been rejected if
fewer than 240 or more than 274 graphs had been seen in
the TA group (Table 2). On the basis of the small confidence
interval (1.7%), it was concluded that the test was suffi-
ciently powerful to detect a difference between the 2 groups
if one truly existed.
Chest tube drainage was significantly reduced in the TA
group at 6, 12, and 24 hours after surgery (Figure 1). This
reduction resulted in decreased requirements for blood
product transfusion in the TA group when compared with
placebo. Packed red blood cells were transfused in 16%
versus 25% (P  .037), fresh frozen plasma was transfused
in 1.4% versus 7.3% (P  .011), and platelets were trans-
fused in 0.7% versus 3.6% (P  .08) of patients in the TA
and placebo groups, respectively. One (0.7%) patient in the
TA group and 15 (9.0%) patients in the placebo group had
excessive chest tube drainage (750 mL over the first 6
hours after surgery; P  .001). The proportion of patients
receiving open-label TA was lower in the TA group than in
the placebo group (2.8% vs 14.6%; P .001). There was no
difference between groups with respect to postoperative
morbidity and mortality (Table 3).
Discussion
In this study, we have shown for the first time that early
SVG patency is not compromised by the perioperative use
of the synthetic lysine analog TA. Induction of the fibrino-
lytic system is advocated as one of the major components of
TABLE 2. Magnetic resonance imaging (MRI) assessment
of saphenous vein graft patency
Variable
TA group
(n  118)
Placebo group
(n  119)
No. grafts performed 297 265
Grafts seen on MRI, n (%)
[95% CI]
253 (85.2)
[83.5-86.9]
231 (87.2)
[85.5-88.9]
Grafts not seen on MRI, n (%)
[95% CI]
44 (14.8)
[13.1-16.5]
34 (12.8)
[11.1-14.6]
TA, Tranexamic acid; CI, confidence interval.perioperative coagulopathy.17 Perioperative use of antifi-
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loss and blood product requirements after cardiac sur-
gery.13,18,19 Previously, we13 showed that the use of TA
during elective CABG surgery reduced the proportion of
patients with a 6-hour postoperative blood loss in excess of
750 mL from 18% to 2%. Furthermore, in a dose-escalating
study, we identified that TA 100 mg/kg seemed to be an
optimal dose to achieve this goal.14 Consequently, this dose
was chosen in our current study. This study confirmed our
previous findings that TA considerably reduced postopera-
tive bleeding and, consequently, blood product transfusion
rates, thus minimizing the risks of allogeneic blood trans-
fusion and resulting in potential overall cost reduction.
The main concern with the administration of antifibrino-
lytic agents during the perioperative period remains reduced
coronary bypass graft patency and other thrombotic com-
plications. The standard by which the operative results must
be judged is high. It is well known that the early patency
rate for ITA anastomoses completed with standard tech-
niques is greater than 94%.20,21 However, vein graft patency
rates do not fare so well. Even without the use of antifi-
brinolytic agents, 5% to 15% of all grafts may occlude in the
early postoperative period, with a possible recurrence of
myocardial ischemia, infarction, or even death.22,23 Further-
more, SVG patency at 1 year after CABG surgery varies
from 77% to 88%.21,24
Extensive work has been performed to investigate the
safety aspects of aprotinin and early graft occlusion after
CABG surgery. A multicenter International Multicenter
Figure 1. Postoperative chest tube drainage at 3 consecutive time
periods. Data analyzed with Mann-Whitney test and shown in the
figure as mean and SD. *P < .0001. Œ, Tranexamic acid; ,
placebo.Aprotinin Graft Patency Experience trial evaluated 870 pri-
312 The Journal of Thoracic and Cardiovascular Surgery ● Augumary CABG patients randomized to receive either aprotinin
or placebo. Coronary graft occlusion rates were evaluated
by postoperative angiography. There was a significant in-
crease in early graft occlusion rates in aprotinin-treated
patients: 15.4% versus 10.9% in the placebo group. More-
over, in some participating sites, early SVG occlusion rates
were as high as 23% in the aprotinin group, compared with
12.4% in the placebo group. However, there was no differ-
ence in mortality and myocardial infarction rates between
the 2 groups despite sufficient power of the study to detect
such a difference.16
Although coronary angiography is still considered a
gold standard in the assessment of graft patency after
coronary revascularization surgery, this technique uses
intra-arterial catheterization and injections of contrast
medium, with significant x-ray exposure and potential
complications.25,26 Recent advances in magnetic reso-
nance coronary angiography have made it a suitable
method for visualizing coronary arteries—and, particu-
larly, venous grafts, which are larger in diameter—in a
way that is less invasive and expensive than conventional
angiography.27,28 The cardiovascular MRI provides ac-
curate and highly reproducible tomographic images in
any desired anatomic plane and is not limited by acoustic
windows. It is a safe and noninvasive method with no risk
of ionizing radiation that provides accurate information
on cardiac structures, blood flow, and angiography. Sev-
eral studies have investigated the sensitivity and speci-
ficity of MRI in assessing graft patency after CABG
surgery. White and colleagues29 found a 78% predictive
accuracy of MRI in determining the graft patency in 25
patients (72 grafts) after CABG surgery. Rubinstein and
colleagues30 studied 20 patients (47 grafts) by using MRI
versus cardiac catheterization. The reported sensitivity
and specificity of MRI were 92% and 85%, respective-
ly.30 A similar study was conducted by Aurigemma and
associates,31 who analyzed data from 20 patients (40
grafts) by using cine MRI and found that the sensitivity
and specificity of MRI were 88% and 100%, respectively,
when compared with conventional cardiac catheteriza-
tion. More recently, Langerak and associates32 described
TABLE 3. Postoperative complications
Complication
TA group
(n  147)
Placebo group
(n  165)
Atrial fibrillation 22 (14.9) 23 (13.9)
Cardiac arrest 3 (2.0) 1 (0.6)
Myocardial infarction 2 (1.4) 3 (1.8)
Stroke 1 (0.68) 1 (0.6)
Death 3 (2.0) 1 (0.6)
Data are expressed as absolute number (%). TA, Tranexamic acid.high-resolution magnetic resonance angiography for de-
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Ptection of vein graft disease in patients who presented
with recurrent chest pain after bypass surgery. There was
good agreement between MRI and coronary angiography
for identifying both graft occlusion and graft stenosis,
and the MRI images were judged insufficient in only 10%
of grafts.32 Although at present the MRI has not com-
pletely replaced conventional coronary angiography, fu-
ture developments in magnetic resonance technology will
increase the sensitivity of current methods for assessing
the severity of coronary artery disease, as well as for
guiding surgical revascularization and determining graft
patency after surgery.
The primary objective of this study was to determine the
equivalency of SVG patency rates between the treatment
and placebo groups. Because of the limitations of MRI
software, this study could not determine the overall SVG
patency rates after surgery. However, our results showed
insignificant variation in graft patency rates between the 2
groups, and the actual SVG patency rates could have been
higher only if all constructed grafts had been seen on MRI.
Another limitation of this study relates to lack of assessment
of arterial graft patency. However, to measure ITA graft
patency rates, our sample size would have to be consider-
ably increased. Each patient received on average 1 ITA graft
and 2 to 3 SVGs; consequently, if one were to estimate ITA
graft patency, the sample size would need to be calculated
on the basis of the number of patients participating in the
study, rather than on the number of grafts performed.
Within this study design, we could only speculate that ITA
graft patency rates were comparable in both groups of
patients on the basis of similar rates of postoperative cardiac
complications.
In conclusion, our study has demonstrated that the syn-
thetic lysine analog TA did not seem to compromise SVG
patency rates. TA could be advocated for routine use in
patients undergoing coronary revascularization procedures
with CPB to minimize postoperative bleeding and reduce
perioperative blood product transfusion rates.
We thank the cardiac anesthesiologists, cardiac surgeons, and
nurses of the Cardiovascular Intensive Care Unit at Toronto Gen-
eral Hospital.
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